Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,950 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,826 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04973007 | Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases | terminated | Phase 4 | 10 | University of Colorado, DenverOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05201781 | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | recruiting | Phase 4 | 295 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06084234 | National Liver Cancer Screening Trial(TRACER) | recruiting | Phase 4 | 5,500 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06952660 | Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | recruiting | Phase 4 | 100 | PfizerINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07761351 | A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy(ENCOMPASS) | recruiting | Phase 4 | 550 | Intuitive SurgicalINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07843134 | Suzetrigine Versus Standard Analgesia After Skin Cancer Surgery | not yet recruiting | Phase 4 | 230 | University of MinnesotaOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06651970 | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | recruiting | Phase 4 | 60 | AstraZenecaINDUSTRY | 6 | Sep 24, 2026 | clinicaltrials |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT04145518 | Mechanistic Characterization of Uterine Pain(MCUP) | completed | Phase 4 | 183 | Endeavor HealthOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05144997 | Lorlatinib Continuation Study | active not recruiting | Phase 4 | 76 | PfizerINDUSTRY | 8 | Sep 23, 2026 | clinicaltrials |
| NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | not yet recruiting | Phase 4 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT07706673 | ESCUDDO Long Term Follow Up(ESCUDDO LTFU) | enrolling by invitation | Phase 4 | 13,700 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05237947 | Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial(PRISMA) | active not recruiting | Phase 4 | 5,000 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06099119 | Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.(PERTseverance) | recruiting | Phase 4 | 100 | Hospital Clinico Universitario de SantiagoOTHER | 3 | Sep 21, 2026 | clinicaltrials |
| NCT06603870 | Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis(STREAM-Line) | recruiting | Phase 4 | 330 | Ottawa Hospital Research InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | active not recruiting | Phase 4 | 134 | Novartis PharmaceuticalsINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT00904410 | Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET(CHIMTEP) | completed | Phase 4 | 63 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00911092 | Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer(COL) | completed | Phase 4 | 50 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | active not recruiting | Phase 4 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07303816 | Statins to Prevent Cancer Associated Blood Clots(STAT-CAT) | recruiting | Phase 4 | 4,000 | Brigham and Women's HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05206331 | CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study | completed | Phase 4 | 2,089 | Margarita Louise ZuleyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06049134 | Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy | active not recruiting | Phase 4 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06647342 | The Effect of Reduced Bleomycin in Electrochemotherapy Treatment(BLESS) | recruiting | Phase 4 | 55 | Julie GehlOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.(CPI) | not yet recruiting | Phase 4 | 110 | Centre Antoine LacassagneOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT06908694 | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy(GAINPCCONTROL) | active not recruiting | Phase 4 | 20 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07176689 | Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | recruiting | Phase 4 | 50 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 6 | Sep 14, 2026 | clinicaltrials |
| NCT05979493 | QL Block in Laparoscopic Myomectomy | recruiting | Phase 4 | 80 | Joseph Findley MDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06429761 | Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients(STRIDE) | active not recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06285370 | A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy | completed | Phase 4 | 23 | Kyowa Kirin China Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04016376 | Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction | completed | Phase 4 | 1,507 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06274515 | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies(REMERGE) | recruiting | Phase 4 | 320 | Hoffmann-La RocheINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT07120295 | Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories | recruiting | Phase 4 | 75 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801027 | A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) | not yet recruiting | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05700903 | Contributions to Hypertension With Androgen Deprivation Therapy(ARCH) | terminated | Phase 4 | 10 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03977753 | Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts(EVAsION) | recruiting | Phase 4 | 162 | Labo'LifeINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.(REVIVE) | recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03048084 | Seizure Treatment in Glioma(STING) | recruiting | Phase 4 | 120 | Leiden University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07720726 | Impact of Dysport on PMFF Donor Scar | not yet recruiting | Phase 4 | 50 | Vanderbilt University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07776821 | An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer. | recruiting | Phase 4 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05148494 | TES RCT Fleet Enema vs Oral Mechanical Bowel Prep(TESEO) | recruiting | Phase 4 | 66 | Nova Scotia Health AuthorityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06862219 | A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer | recruiting | Phase 4 | 100 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials